论文部分内容阅读
目的研究阿托伐他汀钙片对冠心病合并高脂血症的调脂疗效,探讨最佳用药剂量。方法 120例冠心病合并高脂血症患者随机分为观察组与对照组,各60例,均在冠心病基础治疗基础上联用阿托伐他汀钙片,观察组40 mg/d,对照组20 mg/d。分别于用药前、用药6周、用药12周行血脂检查,以评定调脂疗效;统计用药期间肝肾功能损害及肌溶解等不良反应发生率。结果所有患者经治疗后总胆固醇(TC)、甘油三脂(TG)、低密度脂蛋白胆固醇(LDL-C)均呈显著下降趋势,而高密度脂蛋白胆固醇(HDL-C)呈显著上升趋势,同时观察组用药6周、用药12周与对照组对比,差异均有统计学意义(P<0.05)。两组不良反应发生率对比,差异无统计学意义(P>0.05)。结论对冠心病合并高血脂患者,可应用阿托伐他汀钙片降血脂,且宜选择高剂量用药方案。
Objective To study the effect of atorvastatin calcium on the lipid-lowering effect of coronary heart disease with hyperlipidemia and to explore the optimal dosage. Methods A total of 120 patients with coronary heart disease complicated with hyperlipidemia were randomly divided into observation group and control group, 60 cases in each group. All of them were treated with atorvastatin calcium tablets on basis of coronary heart disease, 40 mg / d in observation group, 20 mg / d. Respectively before medication, medication for 6 weeks, medication 12 weeks of blood lipids to assess the effect of lipid-lowering drugs; statistical treatment of liver and kidney dysfunction and the incidence of adverse reactions such as muscle lysis. Results After treatment, TC, TG and LDL-C decreased significantly, but HDL-C increased significantly , While the observation group for 6 weeks, 12 weeks compared with the control group, the differences were statistically significant (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion In patients with coronary heart disease complicated with hyperlipidemia, atorvastatin calcium tablets can be used to reduce blood fat, and should choose high-dose drug regimen.